An Exclusive Interview with Joe Hayon,President, Director & Co-Founder
Market Data
Millions are still dependent on
Invasive Mechanical Ventilation
Each year millions and millions suffering from Acute Respiratory Failure end up on Invasive Mechanical Ventilation (IMV), requiring intubation and induced coma. Despite IMV being defined as Life Support, this machine exposes the patient to high risks and ventilator associated complications
This Could Be You!
with a mortality rate that reaches as high as 50%.
INSPIRA™ ART – A New Approach
Targeting to prevent the need for Invasive Mechanical Ventilation, the INSPIRA ART system is a new approach being developed to provide respiratory support with you awake and breathing.
By bypassing the sick lung and going directly into the blood, the INSPIRA ART aims to provide continuous blood oxygenation and carbon dioxide removal, rebalancing oxygen saturation levels in minutes.
How Does It Work?
Disruptive Achievements
The U.S. Patent and Trademark Office (USPTO) has granted Inspira a patent for the INSPIRA ART’s convertible dual lumen cannula device including its Method of Use, with all 20 claims found to be novel, with inventive step and industrial applicability. This year, we expect additional patent grants for INSPIRA ART technologies and Method of Use.
Inspira has signed a strategic OEM agreement with a division of a significant global medical-device corporation for the manufacture of a flow mechanism for the blood oxygenation process in our disruptive products.
Inspira has signed several distribution agreements across US and Europe for our product pipeline targeting up to $480 million in sales (over up-to a 7-year period and pre-conditional on the completion of development and regulatory approvals)
Inspira has a world-class advisory board with renowned key opinion leaders including the president elect of the international Extracorporeal Life Support Organization (ELSO society).
Signed collaboration with Sheba Medical Center (World-renowned hospital in Israel) for INSPIRA ART Technologies
Our business model being designed to create infinite scalability by bundling the INSPIRA ART with disposal kits sold per patient (Gillete Model) could generate annual earning of $1bn per every 500,000 patients, which is about 5% of the total addressable market
INSPIRA™ ART Building Blocks
Being developed for the INSPIRA ART and as a stand-alone device,
the HYLA is a non-invasive optical blood sensor armed with
machine learning based algorithms, aiming to provide
immediate access to key blood parameters.
A clinical study is being conducted at the world -Sheba Medical Center alongside patients undergoing open-heart surgery.
An extracorporeal blood circulation device developed to provide cardiac and pulmonary support for patients undergoing open-heart surgery, performs continuous enrichment of the blood with oxygen and carbon dioxide removal.
A 510(k) submission is planned for the second half of 2023, with regulatory clearance expected in 2024.
Company Milestones
A new class of acute respiratory care.
designed to reduce
the need for Invasive Mechanical Ventilation (IMV)
INSPIRA™
ART System
A non-invasive optical blood sensor
HYLA™
Blood Sensor
ALICE™ Device
An extracorporeal blood circulation device designed to provide cardiac and pulmonary support
NASDAQ: IINN, IINNW
Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information).
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Inspira Technologies (IINN) is a client of RedChip Companies, Inc. IINN agreed to pay RedChip Companies, Inc. a $13,500 monthly cash fee, beginning in May 2022, for 12 months of RedChip investor awareness services.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.